New data for GlaxoSmithKline’s vaccine, Cervarix®, presented at IPV Conference

Key results from three important studies of the cervical cancer vaccine, Cervarix®, will be available as of today at the 25th International Papillomavirus Conference (IPV) in Malmö, Sweden.